https://www.clotbust.com/ Recent content on The Clotbust Review Hugo -- gohugo.io en-us Tue, 01 Sep 2026 00:00:00 +0000 https://www.clotbust.com/10.1016-s1474-44222400369-7/ Tue, 01 Sep 2026 00:00:00 +0000 https://www.clotbust.com/10.1016-s1474-44222400369-7/ GBD 2021 estimates 11.9 million incident strokes (95% UI 10.7-13.2), 7.3 million deaths, 93.8 million prevalent cases, and 160.5 million DALYs in 2021, with 84.1% of stroke DALYs (135.0 million) attributable to 23 risk factors — high systolic blood pressure (56.8% PAF) and ambient particulate matter (16.6%) leading. https://www.clotbust.com/10.1186-s12987-026-00798-2/ Mon, 31 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1186-s12987-026-00798-2/ In a thromboembolic rat stroke model, the 35 kDa claudin-5 isoform 1 transiently rises in ipsilateral cerebrovasculature at 6 h and correlates with 24-hour cerebral edema, neurological deficit, and hemorrhagic transformation but not with infarct volume. https://www.clotbust.com/10.1161-strokeaha.125.054555/ Sun, 30 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1161-strokeaha.125.054555/ In a longitudinal Oxford cohort, most survivors showed cognitive recovery after stroke—mainly in the first 6 months—but acute cognitive burden strongly predicted persistent deficits, and a small subgroup declined over time. https://www.clotbust.com/10.1001-jamaneurol.2026.1706/ Sat, 29 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1001-jamaneurol.2026.1706/ In the HOPE randomized trial, reperfusion-guided systolic blood pressure targets after successful thrombectomy improved 90-day functional independence and reduced hemorrhagic transformation without increasing symptomatic intracranial hemorrhage or mortality. https://www.clotbust.com/10.1161-strokeaha.125.054101/ Thu, 27 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1161-strokeaha.125.054101/ In adults 3 to 18 months after stroke, adding action observation to virtual-reality training improved paretic-hand dexterity more than virtual reality alone, with the between-group advantage persisting at 6 months. https://www.clotbust.com/10.1161-strokeaha.125.054738/ Wed, 26 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1161-strokeaha.125.054738/ In 4,765 patients receiving oral antithrombotic therapy, severe MRI-defined cerebral small vessel disease was associated with functional decline over 24 months even after accounting for major bleeding and ischemic events. https://www.clotbust.com/10.1001-jamaneurol.2025.3151/ Sat, 22 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1001-jamaneurol.2025.3151/ In the MIND trial, minimally invasive surgery with the Artemis device within 72 hours did not significantly reduce 30-day mortality or improve 180-day disability in supratentorial ICH versus medical management alone. https://www.clotbust.com/10.1001-jamaneurol.2023.5093/ Fri, 21 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.1001-jamaneurol.2023.5093/ In 601 Chinese AIS patients with early neurological deterioration, 7-day argatroban + antiplatelet improved 90-d mRS 0–3 (80.5% vs 73.3%, aRR 1.10, P=0.03) without increased sICH (0.9% vs 0.7%). https://www.clotbust.com/10.5853-jos.2025.05386/ Fri, 21 Aug 2026 00:00:00 +0000 https://www.clotbust.com/10.5853-jos.2025.05386/ In a matched multicenter cohort of 746 large-vessel-occlusion patients undergoing bridging therapy, tenecteplase produced nearly twice the thrombus migration of alteplase (19.3% vs 11.3%), concentrated in the first 60 minutes after IVT, and migration independently predicted functional independence. https://www.clotbust.com/welcome/ Fri, 21 Aug 2026 00:00:00 +0000 https://www.clotbust.com/welcome/ Site move in progress. https://www.clotbust.com/deep-dive-andexanet-iche-annexa-i-secondary-analyses/ Thu, 20 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-andexanet-iche-annexa-i-secondary-analyses/ Shorter onset-to-treatment time, larger baseline hematoma volume, higher diastolic BP, and higher prescan growth rate predict HE but not thrombotic events in FXa-inhibitor ICH; andexanet benefit is amplified in the highest-risk quartiles (NNT ~4). https://www.clotbust.com/deep-dive-argatroban-dapt-branch-atherosclerosis-bad-rct/ Wed, 19 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-argatroban-dapt-branch-atherosclerosis-bad-rct/ In 100 Chinese BAD patients with mild stroke, argatroban+DAPT cut early neurological deterioration from 47.1% to 20.4% (RR 2.31, P=0.006) and improved 90-day mRS 0–1 from 68.6% to 87.8% (P=0.025). https://www.clotbust.com/deep-dive-jx10-tms007-late-window-thrombolytic/ Tue, 18 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-jx10-tms007-late-window-thrombolytic/ Phase 2a dose-escalation: JX10 (TMS-007) given 5–12 hours post-LKN had 0% symptomatic ICH vs 2.6% placebo, with a day-90 mRS 0–1 of 40.4% vs 18.4% (P=0.03). https://www.clotbust.com/deep-dive-annexa-i-biomarker-substudy/ Mon, 17 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-annexa-i-biomarker-substudy/ Andexanet cuts anti-FXa activity and raises ETP at 1 hour; both biomarkers independently predict hematoma reduction but ETP rise also predicts more thrombotic events — the therapeutic window is 1 hour, and it cuts both ways. https://www.clotbust.com/deep-dive-perforator-territory-infarction-functional-outcome-lvo-stroke-2025/ Sun, 16 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-perforator-territory-infarction-functional-outcome-lvo-stroke-2025/ In 397 LVO thrombectomy patients (CONTRAST cohort), perforator-territory infarction on post-treatment MRI roughly tripled the odds of worse 90-day mRS (common OR 2.94, 95% CI 1.73–4.98) without significantly worsening 24-h NIHSS. https://www.clotbust.com/deep-dive-mrclean-m2-bridging/ Sat, 15 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-mrclean-m2-bridging/ In 539 Dutch M2 occlusion patients (2014–2018), IVT+EVT vs direct EVT produced better 90-day ordinal mRS (adjusted cOR 1.52, 95% CI 1.04–2.21, P=0.03) without significantly different sICH or recanalization rates. https://www.clotbust.com/deep-dive-etlas2-tadalafil-csvd-2026-08/ Fri, 14 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-etlas2-tadalafil-csvd-2026-08/ In 76 Danish CSVD patients, 3 months of tadalafil 20 mg/day did NOT meet the prespecified ≥90% compliance feasibility threshold (68% vs 94% placebo, OR 0.13, P=0.030), with markedly more AEs (76% vs 36%); a per-protocol WMH volume trend (P=0.054) hints at mechanistic activity. https://www.clotbust.com/optimas-2026-early-vs-delayed-anticoagulation/ Fri, 14 Aug 2026 00:00:00 +0000 https://www.clotbust.com/optimas-2026-early-vs-delayed-anticoagulation/ OPTIMAS subgroup analysis: in 3,619 stroke patients with AF, neither the time of AF diagnosis (before vs. after the index stroke) nor AF subtype (persistent vs. paroxysmal) modifies the effect of early DOAC initiation versus delayed initiation. Persistent AF is independently associated with roughly double the risk of recurrent ischemic stroke compared with paroxysmal AF. https://www.clotbust.com/deep-dive-zodiac-head-of-bed-thrombectomy/ Wed, 12 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-zodiac-head-of-bed-thrombectomy/ ZODIAC stopped at 92 patients (planned 182) after 0° head-of-bed positioning cut pre-thrombectomy END (≥2 NIHSS) from 55% to 2% (HR 34.40, P<0.001); exploratory mortality 4.4% vs 21.7% (P=0.03). https://www.clotbust.com/deep-dive-t-flavor-standard-dose-tenecteplase-vs-low-dose-alteplase/ Tue, 11 Aug 2026 00:00:00 +0000 https://www.clotbust.com/deep-dive-t-flavor-standard-dose-tenecteplase-vs-low-dose-alteplase/ T-FLAVOR (n=218): tenecteplase 0.25 mg/kg doubled pre-thrombectomy substantial reperfusion vs alteplase 0.6 mg/kg (10.3% vs 3.6%; 90% CI 0.89–12.1), meeting phase-2 surrogate threshold despite the conventional 95% CI crossing zero. https://www.clotbust.com/actisave-glenzocimab-thrombolysis-thrombectomy/ Mon, 10 Aug 2026 00:00:00 +0000 https://www.clotbust.com/actisave-glenzocimab-thrombolysis-thrombectomy/ ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis https://www.clotbust.com/cr-interval-poststroke-fatigue-rehab/ Mon, 10 Aug 2026 00:00:00 +0000 https://www.clotbust.com/cr-interval-poststroke-fatigue-rehab/ In a 2-center PROBE RCT (n=43 completers), 8 weeks of home-based supervised HIIT cut poststroke fatigue by 5.35 S-FAS points (95% CI -9.03 to -3.67) and improved VO2peak by 4.48 mL/kg/min. https://www.clotbust.com/lamp-liraglutide-stroke-insulin-resistance/ Mon, 10 Aug 2026 00:00:00 +0000 https://www.clotbust.com/lamp-liraglutide-stroke-insulin-resistance/ In LAMP post-hoc analysis, liraglutide reduced 90-day recurrent stroke from 18.1% to 5.8% (HR 0.30, NNT 8) in patients with HOMA-IR ≥ 2.5; no benefit in patients with preserved insulin sensitivity. https://www.clotbust.com/about/ Mon, 01 Jan 0001 00:00:00 +0000 https://www.clotbust.com/about/ The Clotbust Review is an independent medical-education publication focused on stroke neurology literature. Each article summarizes a published study and places its findings in clinical and methodological context. Editorial policy The site is written for education and discussion.